Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
Question
Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
Direct answer
Stronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance. — bullish pressure on XRAY via earnings beat and FY2026 guidance reaffirmation.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/dentsply-sirona-beats-q2-adjusted-eps-consensus-at-0-52-and-reaffirms-fy26-outlo-bcbbd6
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XRAY | ▲Bull | 1–5 days | earnings beat and FY2026 guidance reaffirmation | 49 |
Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 Outlook
Stronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance. — bullish pressure on XRAY via earnings beat and FY2026 guidance reaffirmation.
Adjusted EPS of $0.52 beat $0.36 consensus; full-year guidance of $1.40-$1.50 EPS reaffirmed.
- SourceAdjusted EPS of $0.52 beat $0.36 consensus; full-year guidance of $1.40-$1.50 EPS reaffirmed.
- TransmissionStronger operational cost control offsets top-line declines, protecting Dentsply Sirona operating cash flow and reaffirming full-year EPS guidance.
- SummaryDentsply Sirona reported Q2 adjusted EPS of $0.52 versus $0.36 expected. Revenues contracted 4.1% YoY, but segment growth in Wellspect reached 7.1%. Management maintained full-year revenue and EPS target ranges.
- XRAYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- XRAY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XRAY price vs. pre-event level
- XRAY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XRAY | Bullishdisagreed | 10.72 2026-09-09 | -2.05% | -5.41% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · news · 2026-09-08
Related catalysts
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 OutlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales GuidanceXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 TargetsXRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 GuidanceALGN XRAY-5.41%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.